BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Remicade is a prescription medication approved by the Food and Drug Administration (FDA) to treat active ankylosing spondylitis and psoriatic arthritis, chronic severe plaque psoriasis, and moderately to severely active cases of rheumatoid arthritis, adult and pediatric Crohn’s disease, and adult and pediatric ulcerative colitis. Remicade may be referred to by its drug name, Infliximab.
Remicade is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Remicade is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Remicade is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
After initial loading doses, Remicade is administered every six or eight weeks by intravenous infusion.
Remicade is available in vial form.
The FDA-approved label for Remicade lists common side effects including headache, cold symptoms, infusion reactions, and abdominal pain.
Rare but serious side effects listed for Remicade include heart and liver failure, blood disorders, severe infections and allergic reactions, lupus-like syndrome, demyelinating disease such as multiple sclerosis, and increased risk for developing certain types of cancer such as lymphoma.
For answers to frequently asked questions about exposure to Infliximab during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.
For more details about this treatment, visit:
Remicade – Janssen